Market Research Logo

Pulmonary Edema Therapeutics Market by Type and Geography - Forecast and Analysis 2019-2023

Global Pulmonary Edema Therapeutics Market: About this market

Technavio’s pulmonary edema therapeutics market analysis considers sales from cardiogenic pulmonary edema and non-cardiogenic pulmonary edema types. Our study also finds the sales of pulmonary edema therapeutics in Asia, Europe, North America, and ROW. In 2018, the cardiogenic pulmonary edema segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of cardiovascular diseases such as carotid artery disease, cardiomyopathy, heart valve problems, and hypertension will play a significant role in the cardiogenic pulmonary edema segment to maintain its market position. Also, our global pulmonary edema therapeutics market report looks at factors such as high prevalence of risk factors, increasing geriatric population, and growing awareness about pulmonary edema. However, adverse effects of available therapeutics, high level of genericization in the market, and availability of substitutes may hamper the growth of the pulmonary edema therapeutics industry over the forecast period.

Global Pulmonary Edema Therapeutics Market: Overview

High prevalence of risk factors

Pulmonary edema is one of the leading causes of death in adults living in developing countries. The high incidence of pulmonary edema is mainly attributed to the availability of high-risk factors such as infections, organ failures, lifestyle habits, trauma, and high altitude. Pulmonary edema can also be caused due to the potential overdosage of drugs such as aspirin and chemotherapy drugs. This high prevalence of risk factors will lead to the expansion of the global pulmonary edema therapeutics market at a CAGR of almost 3% during the forecast period.

Increasing the use of biomarkers for disease diagnosis

The detection of pulmonary edema through biomarkers is gaining prominence in recent diagnostic evaluations. A biomarker is a measurable indicator of a specific biological state or condition, including a pathogenic process. Pulmonary edema is diagnosed by clinical evaluation and imaging tests, which are the most common methods. Blood tests also play a crucial role in identifying the disease through biomarkers present in the blood. The use of biomarkers is less expensive than other evaluation tests. Moreover, these makers can detect other heart or kidney-related diseases. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global pulmonary edema therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global pulmonary edema therapeutics market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pulmonary edema therapeutics manufacturers, that include AbbVie Inc., Bausch Health Companies Inc., Johnson & Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Also, the pulmonary edema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


  • Executive summary
  • Scope of the report
    • Preface
      • Table Product overview
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global pharmaceuticals market
      • Table Segments of global pharmaceuticals market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by type
    • Table Product - Market share 2018-2023 (%)
    • Comparison by type
      • Table Comparison by type
    • Cardiogenic pulmonary edema - Market size and forecast 2018-2023
      • Table Cardiogenic pulmonary edema - Market size and forecast 2018-2023 ($ millions)
      • Table Cardiogenic pulmonary edema - Year-over-year growth 2019-2023 (%)
    • Non-cardiogenic pulmonary edema - Market size and forecast 2018-2023
      • Table Non-cardiogenic pulmonary edema - Market size and forecast 2018-2023 ($ millions)
      • Table Non-cardiogenic pulmonary edema - Year-over-year growth 2019-2023 (%)
    • Market opportunity by type
      • Table Market opportunity by type
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in North America
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Europe
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Asia
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in ROW
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
      • Table Impact of drivers and challenges
  • Market trends
    • Increasing use of biomarkers for disease diagnosis
    • Strategic alliances
    • Increase in funding for research on respiratory diseases
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
    • Competitive scenario
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • AbbVie Inc.
      • Table AbbVie Inc. - Vendor overview
      • Table AbbVie Inc. - Business segments
      • Table AbbVie Inc. - Organizational developments
      • Table AbbVie Inc. - Geographic focus
      • Table AbbVie Inc. - Key offerings
      • Table AbbVie Inc. - Key customers
    • Bausch Health Companies Inc.
      • Table Bausch Health Companies Inc. - Vendor overview
      • Table Bausch Health Companies Inc. - Business segments
      • Table Bausch Health Companies Inc. - Organizational developments
      • Table Bausch Health Companies Inc. - Geographic focus
      • Table Bausch Health Companies Inc. - Segment focus
      • Table Bausch Health Companies Inc. - Key offerings
      • Table Bausch Health Companies Inc. - Key customers
    • Johnson & Johnson Services Inc.
      • Table Johnson & Johnson Services Inc. - Vendor overview
      • Table Johnson & Johnson Services Inc. - Business segments
      • Table Johnson & Johnson Services Inc. - Organizational developments
      • Table Johnson & Johnson Services Inc. - Geographic focus
      • Table Johnson & Johnson Services Inc. - Segment focus
      • Table Johnson & Johnson Services Inc. - Key offerings
      • Table Johnson & Johnson Services Inc. - Key customers
    • Lupin Ltd.
      • Table Lupin Ltd. - Vendor overview
      • Table Lupin Ltd. - Business segments
      • Table Lupin Ltd. - Organizational developments
      • Table Lupin Ltd. - Geographic focus
      • Table Lupin Ltd. - Key offerings
      • Table Lupin Ltd. - Key customers
    • Merck & Co. Inc.
      • Table Merck & Co. Inc. - Vendor overview
      • Table Merck & Co. Inc. - Business segments
      • Table Merck & Co. Inc. - Organizational developments
      • Table Merck & Co. Inc. - Geographic focus
      • Table Merck & Co. Inc. - Segment focus
      • Table Merck & Co. Inc. - Key offerings
      • Table Merck & Co. Inc. - Key customers
    • Mylan NV
      • Table Mylan NV - Vendor overview
      • Table Mylan NV - Product segments
      • Table Mylan NV - Organizational developments
      • Table Mylan NV - Geographic focus
      • Table Mylan NV - Segment focus
      • Table Mylan NV - Key offerings
      • Table Mylan NV - Key customers
    • Novartis AG
      • Table Novartis AG - Vendor overview
      • Table Novartis AG - Business segments
      • Table Novartis AG - Organizational developments
      • Table Novartis AG - Geographic focus
      • Table Novartis AG - Segment focus
      • Table Novartis AG - Key offerings
      • Table Novartis AG - Key customers
    • Pfizer Inc.
      • Table Pfizer Inc. - Vendor overview
      • Table Pfizer Inc. - Business segments
      • Table Pfizer Inc. - Organizational developments
      • Table Pfizer Inc. - Geographic focus
      • Table Pfizer Inc. - Segment focus
      • Table Pfizer Inc. - Key offerings
      • Table Pfizer Inc. - Key customers
    • Sanofi
      • Table Sanofi - Vendor overview
      • Table Sanofi - Business segments
      • Table Sanofi - Organizational developments
      • Table Sanofi - Geographic focus
      • Table Sanofi - Segment focus
      • Table Sanofi - Key offerings
      • Table Sanofi - Key customers
    • Teva Pharmaceutical Industries Ltd.
      • Table Teva Pharmaceutical Industries Ltd. - Vendor overview
      • Table Teva Pharmaceutical Industries Ltd. - Business segments
      • Table Teva Pharmaceutical Industries Ltd. - Organizational developments
      • Table Teva Pharmaceutical Industries Ltd. - Segment focus
      • Table Teva Pharmaceutical Industries Ltd. - Key offerings
      • Table Teva Pharmaceutical Industries Ltd. - Key customers
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
    • Definition of market positioning of vendors
      • Table Definition of market positioning of vendors
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report